抗Ku抗体相关间质性肺病的特征与结局:60例回顾性研究
这项法国多中心回顾性研究纳入154例抗Ku抗体阳性患者,其中60例(39%)合并间质性肺病(ILD),中位随访期间75%患者出现ILD进展。男性与ILD进展相关,基线肺纤维化与校正后生存率降低相关,提示对抗Ku抗体阳性患者应系统筛查和监测ILD。
要点
- 抗Ku抗体阳性患者中39%合并ILD,80%在自身免疫病诊断时即存在ILD。
- 75%的ILD患者在中位4年内进展,男性与进展风险升高相关。
- 基线肺纤维化与校正后生存率降低独立相关。
核心结论
- 抗Ku抗体阳性患者中ILD发生率为39%,其中75%出现进展,应重视系统筛查与监测。
- 男性与ILD进展独立相关(aHR 2.7;95% CI 1.4至5.2)。
- 基线肺纤维化与校正年龄和心脏受累后生存率降低独立相关(aHR 6.5,95% CI 1.5至28.2)。
研究设计与样本
- 观察性、多中心、回顾性研究,覆盖法国10家大学医院,时间范围为2010年1月至2025年6月。
- 纳入154例抗Ku抗体阳性患者,其中60例(39%)合并ILD;女性占68%,中位年龄56岁。
- ILD进展定义参考ATS/ERS/JRS/ALAT临床实践指南,但应用于整个随访期而非12个月窗口。
- 采用Cox比例风险模型分析至ILD进展的时间。
主要发现
- 154例抗Ku抗体阳性患者中,51例为特发性炎性肌病,46例为系统性红斑狼疮,30例为干燥病,27例为系统性硬化。
- 60例ILD患者中,主要模式为纤维化型非特异性间质性肺炎(27%,n=16)。
- 48例(80%)患者在自身免疫病诊断时已存在ILD。
- 严格应用12个月截断值时,仅6例患者符合进展性纤维化性ILD定义。
关键数值与推荐
- ILD进展定义参考ATS/ERS/JRS/ALAT临床实践指南,但应用于整个随访期以捕捉所有临床有意义的进展事件。
- 男性与ILD进展的校正风险比为2.7(95% CI 1.4至5.2)。
- 基线肺纤维化与生存率降低的校正风险比为6.5(95% CI 1.5至28.2),校正因素包括ILD诊断时年龄和心脏受累。
临床怎么用
- 对抗Ku抗体阳性患者应系统筛查ILD,尤其在自身免疫病诊断时。
- 对合并ILD的抗Ku抗体阳性患者需长期监测进展,男性及基线肺纤维化患者风险更高。
- 基线肺纤维化提示预后较差,应加强随访和生存评估。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- ILD进展定义应用于整个随访期而非12个月窗口,与指南标准时间框架不同。
- 样本量有限(60例ILD患者),可能影响统计效能和结果外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anti-Ku antibodies (Abs) are rare and detected in various autoimmune diseases (AIDs), presenting in various phenotypes, potentially affecting different organs including the lungs. This study aimed to describe the characteristics and evolution of interstitial lung disease (ILD) in anti-Ku-positive patients. METHODS: An observational, multicentre, retrospective study was conducted across 10 French University Hospitals between January 2010 and June 2025, including patients with anti-Ku Abs with ILD. Clinical data and all pulmonary function tests and chest CT scans available were reviewed for this study. ILD progression was defined using criteria inspired by the American Thoracic Society/European Respiratory Society/Japenese Respiratory Society/Asociación Latinoamericana de Tórax Clinical Practice Guidelines, applied across the entire follow-up period rather than within the 12-month timeframe, to capture all clinically meaningful progression events. To account for event timing, time to ILD progression was analysed as a time-to-event outcome using Cox proportional hazards models. RESULTS: Among 154 anti-Ku-positive patients (51 with idiopathic inflammatory myopathy, 46 with systemic lupus erythematosus, 30 with Sjögren's disease, 27 with systemic sclerosis), 60 (39%) had ILD (68% women, median age 56 years). The predominant ILD pattern was fibrotic non-specific interstitial pneumonia (27%, n=16). ILD was already present at AID diagnosis in 48 patients (80%). Forty-five (75%) patients progressed after a median time of 4 (2-11) years. Male sex (adjusted HR (aHR) 2.7; 95% CI 1.4 to 5.2) was associated with ILD progression. When the 12-month cut-off was strictly applied, only six patients fulfilled the progressive fibrosing ILD definition. Baseline pulmonary fibrosis was present in 34 (57%) patients and was associated with a reduced survival when adjusting for age at ILD diagnosis and cardiac involvement (aHR 6.5, 95% CI 1.5 to 28.2). CONCLUSION: ILD occurred in 39% of anti-Ku-positive patients and progressed in 75% of them, underscoring the importance of systematic ILD screening and monitoring in these patients.
引用
- Robert M, Nguyen Y, Debray MP, et al. Characteristics and outcomes of anti-Ku antibody-associated interstitial lung disease: a retrospective study of 60 patients. RMD Open. 2026. PMID: 42508943. doi:10.1136/rmdopen-2026-006943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。